Ignite Creation Date:
2024-05-05 @ 10:31 PM
Last Modification Date:
2024-10-26 @ 10:20 AM
Study NCT ID:
NCT01128634
Status:
COMPLETED
Last Update Posted:
2017-06-14
First Post:
2010-05-20
Brief Title:
Pharmacokinetic and Safety of GSK573719 and GW642444 Administered Individually and Concurrently With Verapamilin in Healthy Subjects
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Single-Centre Randomised Open-label Study to Evaluate the Effects of Steady-State Verapamil a Moderate P-Glycoprotein and CYP3A4 Inhibitor on the Pharmacokinetics of GSK573719 and GSK573719 in Combination With GW642444
Status:
COMPLETED
Status Verified Date:
2017-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to see if the Pharmacokinetics and the Safety Profile of GSK573719 and GSK573719GW642444 are effected by concurrent dosing with the PGP inhibitor verapamil
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None